Lactoferrin (LF) is a multifunctional glycoprotein that plays an important role in native immune defense against infections, including human herpetic viruses, such as cytomegalovirus and herpes simplex virus types 1 and 2. However, its anti-Epstein-Barr virus (EBV, a γ-herpesvirus) function has not been reported in the literature. EBV is widespread in all human populations and is believed to be linked to tumorigenesis, such as lymphomas and nasopharyngeal carcinoma (NPC). We previously reported that LF expressed a significantly lower level in NPC tissues and was a likely tumor suppressor. Since EBV infection is a major carcinogen of NPC development, we investigated the effect of LF on EBV infection and found that LF could protect human primary B lymphocytes and nasopharyngeal epithelial cells from EBV infection, but had no effect on EBV genome DNA replication. LF prevented EBV infection of primary B cells mediated by its direct binding to the EBV receptor (CD21) on the B-cell surface. Tissue array immunohistochemistry revealed that LF expression was significantly downregulated in NPC specimens, in which high EBV viral capsid antigen-IgA levels were observed. These data suggest that LF may inhibit EBV infection and that its downregulation could contribute to NPC development.

Keywords:
Lactoferrin, Epstein-Barr virus, Nasopharyngeal carcionma, CD21
1.
Legrand D, Mazurier J: A critical review of the roles of host lactoferrin in immunity. Biometals 2010;23:365–376.
2.
Teng CT: Lactoferrin: the path from protein to gene. Biometals 2010;23:359–364.
3.
Rodrigues L, Teixeira J, Schmitt F, Paulsson M, Mansson HL: Lactoferrin and cancer disease prevention. Crit Rev Food Sci Nutr 2009;49:203–217.
4.
Gonzalez-Chavez SA, Arevalo-Gallegos S, Rascon-Cruz Q: Lactoferrin: structure, function and applications. Int J Antimicrob Agents 2009;33:301, e301–e308.
5.
Beljaars L, van der Strate BW, Bakker HI, Reker-Smit C, van Loenen-Weemaes AM, Wiegmans FC, Harmsen MC, Molema G, Meijer DK: Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. Antiviral Res 2004;63:197–208.
6.
Valimaa H, Tenovuo J, Waris M, Hukkanen V: Human lactoferrin but not lysozyme neutralizes HSV-1 and inhibits HSV-1 replication and cell-to-cell spread. Virol J 2009;6:53.
7.
Jenssen H, Sandvik K, Andersen JH, Hancock RE, Gutteberg TJ: Inhibition of HSV cell-to-cell spread by lactoferrin and lactoferricin. Antiviral Res 2008;79:192–198.
8.
Groot F, Geijtenbeek TB, Sanders RW, Baldwin CE, Sanchez-Hernandez M, Floris R, van Kooyk Y, de Jong EC, Berkhout B: Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN-gp120 interaction. J Virol 2005;79:3009–3015.
9.
Berkhout B, Floris R, Recio I, Visser S: The antiviral activity of the milk protein lactoferrin against the human immunodeficiency virus type 1. Biometals 2004;17:291–294.
10.
Kaito M, Iwasa M, Fujita N, Kobayashi Y, Kojima Y, Ikoma J, Imoto I, Adachi Y, Hamano H, Yamauchi K: Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin. J Gastroenterol Hepatol 2007;22:1894–1897.
11.
Hara K, Ikeda M, Saito S, Matsumoto S, Numata K, Kato N, Tanaka K, Sekihara H: Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res 2002;24:228.
12.
Drobni P, Naslund J, Evander M: Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Res 2004;64:63–68.
13.
Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757–768.
14.
Nemerow GR, Wolfert R, McNaughton ME, Cooper NR: Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol 1985;55:347–351.
15.
Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA: EBV persistence in memory B cells in vivo. Immunity 1998;9:395–404.
16.
Shannon-Lowe CD, Neuhierl B, Baldwin G, Rickinson AB, Delecluse HJ: Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. Proc Natl Acad Sci USA 2006;103:7065–7070.
17.
Tao Q, Chan AT: Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007;9:1–24.
18.
Kuhara T, Iigo M, Itoh T, Ushida Y, Sekine K, Terada N, Okamura H, Tsuda H: Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 2000;38:192–199.
19.
Tsuda H, Sekine K, Fujita K, Ligo M: Cancer prevention by bovine lactoferrin and underlying mechanisms – a review of experimental and clinical studies. Biochem Cell Biol 2002;80:131–136.
20.
Zhou Y, Zeng Z, Zhang W, Xiong W, Wu M, Tan Y, Yi W, Xiao L, Li X, Huang C, Cao L, Tang K, Shen S, Li G: Lactotransferrin: a candidate tumor suppressor-deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer 2008;123:2065–2072.
21.
Zhang H, Feng X, Liu W, Jiang X, Shan W, Huang C, Yi H, Zhu B, Zhou W, Wang L, Liu C, Zhang L, Jia W, Huang W, Li G, Shi J, Wanggou S, Yao K, Ren C: Underlying mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell lines. J Cell Biochem 2011;112:1832–1843.
22.
Gaudreault E, Fiola S, Olivier M, Gosselin J: Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J Virol 2007;81:8016–8024.
23.
Junying J, Herrmann K, Davies G, Lissauer D, Bell A, Timms J, Reynolds GM, Hubscher SG, Young LS, Niedobitek G, Murray PG: Absence of Epstein-Barr virus DNA in the tumor cells of European hepatocellular carcinoma. Virology 2003;306:236–243.
24.
Gao J, Li X, Li G: Identification of EBV chromosomal integration sites in Raji cells by fluorescence in situ hybridization. J Cent South Univ Med Sci 2009;34:13–19.
25.
Zhou HD, Li XL, Li GY, Zhou M, Liu HY, Yang YX, Deng T, Ma J, Sheng SR: Effect of SPLUNC1 protein on the Pseudomonas aeruginosa and Epstein-Barr virus. Mol Cell Biochem 2008;309:191–197.
26.
Zeng ZY, Zhou YH, Zhang WL, Xiong W, Fan SQ, Li XL, Luo XM, Wu MH, Yang YX, Huang C, Cao L, Tang K, Qian J, Shen SR, Li GY: Gene expression profiling of nasopharyngeal carcinoma reveals the abnormally regulated Wnt signaling pathway. Hum Pathol 2007;38:120–133.
27.
Ikeda M, Nozaki A, Sugiyama K, Tanaka T, Naganuma A, Tanaka K, Sekihara H, Shimotohno K, Saito M, Kato N: Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res 2000;66:51–63.
28.
Deng L, Jing N, Tan G, Zhou M, Zhan F, Xie Y, Cao L, Li G: A common region of allelic loss on chromosome region 3p25.3–26.3 in nasopharyngeal carcinoma. Genes Chromosomes Cancer 1998;23:21–25.
29.
Xiong W, Zeng ZY, Xia JH, Xia K, Shen SR, Li XL, Hu DX, Tan C, Xiang JJ, Zhou J, Deng H, Fan SQ, Li WF, Wang R, Zhou M, Zhu SG, Lu HB, Qian J, Zhang BC, Wang JR, Ma J, Xiao BY, Huang H, Zhang QH, Zhou YH, Luo XM, Zhou HD, Yang YX, Dai HP, Feng GY, Pan Q, Wu LQ, He L, Li GY: A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res 2004;64:1972–1974.
30.
Shah KM, Young LS: Epstein-Barr virus and carcinogenesis: beyond Burkitt’s lymphoma. Clin Microbiol Infect 2009;15:982–988.
31.
Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P, Rosato A: The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010;95:1769–1777.
32.
Jenssen H, Hancock RE: Antimicrobial properties of lactoferrin. Biochimie 2009;91:19–29.
33.
Jenssen H: Anti herpes simplex virus activity of lactoferrin/lactoferricin – an example of antiviral activity of antimicrobial protein/peptide. Cell Mol Life Sci 2005;62:3002–3013.
34.
van der Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK: Antiviral activities of lactoferrin. Antiviral Res 2001;52:225–239.
35.
Ji ZS, Mahley RW: Lactoferrin binding to heparan sulfate proteoglycans and the LDL receptor-related protein. Further evidence supporting the importance of direct binding of remnant lipoproteins to HSPG. Arterioscler Thromb 1994;14:2025–2031.
36.
WuDunn D, Spear PG: Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 1989;63:52–58.
37.
Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M: Human papillomavirus infection requires cell surface heparan sulfate. J Virol 2001;75:1565–1570.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.